Drug
Spesolimab clinical trials
Also written BI 655130 and Spevigo®.
Keep track of what changes. Save the spesolimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
32 studies that test it; most in 2019 (6)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 6 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 31 · Other 1
Boehringer Ingelheim (28) · LEO Pharma (3) · Icahn School of Medicine at Mount Sinai (1)
Studies
Open first, then newest update. How each study uses spesolimab is read from its arms, and is right about nine times in ten.
Testing it · 32
- A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma GangrenosumRecruitingPhase 3LEO PharmaNCT06624670Written as Spesolimab
- A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated FlaresCompletedPhase 4LEO PharmaNCT06013969Written as Spesolimab
- Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous StudyActive, not recruitingPhase 2LEO PharmaNCT03886246Written as Spesolimab
- A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With SpesolimabTerminatedPhase 2/3Boehringer IngelheimNCT06241573Written as Spesolimab
- Spesolimab in Pyoderma GangrenosumTerminatedPhase 2Icahn School of Medicine at Mount SinaiNCT06092216Written as Spesolimab
- A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton SyndromeTerminatedPhase 2/3Boehringer IngelheimNCT05856526Written as Spesolimab - solution for infusion
- A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical TrialCompletedPhase 2Boehringer IngelheimNCT04876391Written as Spesolimab 1200 mg
- Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis SuppurativaCompletedPhase 2/3Boehringer IngelheimNCT05819398Written as Spesolimab i.v.
- An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment OptionsCompletedPhase 3Boehringer IngelheimNCT05239039Written as spesolimab
- BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative ColitisCompletedPhase 2Boehringer IngelheimNCT03648541Written as Spesolimab
- A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is ToleratedCompletedPhase 2Boehringer IngelheimNCT03822832Written as BI 655130
- A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular PsoriasisCompletedPhase 2Boehringer IngelheimNCT04399837Written as Spesolimab
- A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis SuppurativaCompletedPhase 2Boehringer IngelheimNCT04762277Written as Spesolimab - solution for infusion
- A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With SpesolimabTerminatedPhase 2Boehringer IngelheimNCT04493424Written as Spesolimab
- A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current TherapyCompletedPhase 2Boehringer IngelheimNCT03123120Written as Spesolimab
- Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular PsoriasisCompletedPhase 2Boehringer IngelheimNCT03782792Written as Spesolimab
- Initial Dosing of BI 655130 in Palmoplantar Pustulosis PatientsCompletedPhase 2Boehringer IngelheimNCT03135548Written as Spesolimab (low dose)
- BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative ColitisCompletedPhase 2/3Boehringer IngelheimNCT03482635Written as Spesolimab
- A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar PustulosisCompletedPhase 2Boehringer IngelheimNCT04015518Written as Spesolimab
- This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the PatientsCompletedPhase 2Boehringer IngelheimNCT03100864Written as Spesolimab
Codes
What other systems call spesolimab · ClinicalTrials.gg INT001523
- MeSH (NLM) C000712973spesolimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 5IB2J79MCXSPESOLIMABConfirmed FDA, NLM, Wikidata
- RxNorm 2610417One source FDA
- Wikidata Q111172579spesolimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166849SpesolimabOne source FDA
- DrugBank DB15626One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000712973 | spesolimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 5IB2J79MCX | SPESOLIMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2610417 | — | One source FDA |
| Wikidata | Q111172579 | spesolimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166849 | Spesolimab | One source FDA |
| DrugBank | DB15626 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.